IL245159B - Genetic markers of an antipsychotic drug for weight gain and methods of using them - Google Patents
Genetic markers of an antipsychotic drug for weight gain and methods of using themInfo
- Publication number
- IL245159B IL245159B IL245159A IL24515916A IL245159B IL 245159 B IL245159 B IL 245159B IL 245159 A IL245159 A IL 245159A IL 24515916 A IL24515916 A IL 24515916A IL 245159 B IL245159 B IL 245159B
- Authority
- IL
- Israel
- Prior art keywords
- methods
- weight gain
- genetic markers
- induced weight
- antipsychotic induced
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 230000004584 weight gain Effects 0.000 title 1
- 235000019786 weight gain Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892094P | 2013-10-17 | 2013-10-17 | |
| PCT/CA2014/051000 WO2015054792A1 (en) | 2013-10-17 | 2014-10-17 | Genetic markers for antipsychotic induced weight gain and methods for use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL245159A0 IL245159A0 (en) | 2016-06-30 |
| IL245159B true IL245159B (en) | 2020-10-29 |
Family
ID=52827506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245159A IL245159B (en) | 2013-10-17 | 2016-04-17 | Genetic markers of an antipsychotic drug for weight gain and methods of using them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10301678B2 (https=) |
| EP (2) | EP3561076A1 (https=) |
| JP (1) | JP6524073B2 (https=) |
| KR (1) | KR102252926B1 (https=) |
| CN (1) | CN106029901A (https=) |
| AU (1) | AU2014336928B2 (https=) |
| CA (1) | CA2943951C (https=) |
| ES (1) | ES2728072T3 (https=) |
| IL (1) | IL245159B (https=) |
| PT (1) | PT3058106T (https=) |
| SG (1) | SG11201602998QA (https=) |
| WO (1) | WO2015054792A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016085A2 (pt) * | 2018-02-09 | 2020-12-15 | Metabolomic Diagnostics Limited | Métodos de previsão de nascimento prematuro a partir de pré-eclâmpsia usando biomarcadores metabólicos e proteicos |
| CN110317868B (zh) * | 2019-08-09 | 2020-05-19 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN117547526A (zh) * | 2023-10-24 | 2024-02-13 | 首都医科大学附属北京朝阳医院 | γ-氨基丁酸GABA在制备防治奥氮平诱发的不良反应药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| DK1921169T3 (da) | 1993-11-12 | 2012-06-04 | Phri Properties Inc | Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits |
| US20030104453A1 (en) | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
| US8012718B2 (en) | 2006-03-31 | 2011-09-06 | Genomas, Inc. | Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs |
| US20070292962A1 (en) * | 2006-04-10 | 2007-12-20 | Duke University | Methods and compositions for genetic markers for autism |
| US7795033B2 (en) | 2007-03-19 | 2010-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods to predict the outcome of treatment with antidepressant medication |
| US8476012B2 (en) | 2008-04-18 | 2013-07-02 | Genomas, Inc. | Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| EP2791352A1 (en) | 2011-12-14 | 2014-10-22 | Astrazeneca AB | Gabr-a2 diagnostic |
-
2014
- 2014-10-17 EP EP19159011.6A patent/EP3561076A1/en not_active Withdrawn
- 2014-10-17 AU AU2014336928A patent/AU2014336928B2/en not_active Ceased
- 2014-10-17 WO PCT/CA2014/051000 patent/WO2015054792A1/en not_active Ceased
- 2014-10-17 EP EP14854407.5A patent/EP3058106B1/en not_active Not-in-force
- 2014-10-17 CA CA2943951A patent/CA2943951C/en active Active
- 2014-10-17 PT PT14854407T patent/PT3058106T/pt unknown
- 2014-10-17 ES ES14854407T patent/ES2728072T3/es active Active
- 2014-10-17 US US15/029,955 patent/US10301678B2/en active Active
- 2014-10-17 SG SG11201602998QA patent/SG11201602998QA/en unknown
- 2014-10-17 CN CN201480069450.4A patent/CN106029901A/zh active Pending
- 2014-10-17 KR KR1020167012720A patent/KR102252926B1/ko not_active Expired - Fee Related
- 2014-10-17 JP JP2016524143A patent/JP6524073B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-17 IL IL245159A patent/IL245159B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3058106B1 (en) | 2019-02-27 |
| US10301678B2 (en) | 2019-05-28 |
| CA2943951A1 (en) | 2015-04-23 |
| SG11201602998QA (en) | 2016-05-30 |
| ES2728072T3 (es) | 2019-10-22 |
| CA2943951C (en) | 2022-05-31 |
| CN106029901A (zh) | 2016-10-12 |
| EP3058106A4 (en) | 2017-06-07 |
| PT3058106T (pt) | 2019-05-30 |
| JP6524073B2 (ja) | 2019-06-05 |
| JP2016534715A (ja) | 2016-11-10 |
| AU2014336928B2 (en) | 2020-07-16 |
| EP3058106A1 (en) | 2016-08-24 |
| US20160237499A1 (en) | 2016-08-18 |
| WO2015054792A1 (en) | 2015-04-23 |
| IL245159A0 (en) | 2016-06-30 |
| KR102252926B1 (ko) | 2021-05-20 |
| KR20160098188A (ko) | 2016-08-18 |
| EP3561076A1 (en) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277917B (en) | jak2 and alk2 inhibitors and their use | |
| ZA201509201B (en) | Soybean transgenic event mon87751 and methods for detection and use thereof | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| GB201318201D0 (en) | Weight Sensing | |
| PL2800738T3 (pl) | Związki heterocykliczne i sposoby ich stosowania | |
| AP2016009207A0 (en) | Genetic markers and uses therefor | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405257B (en) | Heterocyclic compounds and methods for their use | |
| PL2964767T3 (pl) | Geny kodujące toksyny i sposoby ich zastosowania | |
| IL244214A0 (en) | Thienopiperidine derivative and its use | |
| IL243433A0 (en) | Titanium bibory layers and their production | |
| ZA201405392B (en) | Substituted phenylimidazopyrazoles and use thereof | |
| PT2708607T (pt) | Marcadores genéticos para myb28 | |
| IL246417A0 (en) | Genetic markers related to suicide risk and methods of using them | |
| SG10201708046YA (en) | Nanoprobe-Based Genetic Testing | |
| IL245159B (en) | Genetic markers of an antipsychotic drug for weight gain and methods of using them | |
| EP2971114A4 (en) | METHODS AND COMPOSITIONS FOR ASSESSING GENETIC MARKERS | |
| GB201308321D0 (en) | Top marker | |
| EP3065826A4 (en) | Genetic markers of antipsychotic response | |
| TWI559851B (en) | Watering and feeding dual-purpose vessel construction | |
| GB201204745D0 (en) | Identifying proximity and location | |
| GB201303123D0 (en) | Cell surface markers | |
| GB201303124D0 (en) | Cell surface markers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |